CRBU, US1420381089

Wall Street Zen downgrades Caribou Biosciences stock to Sell

Published on 10/05/2026 at 18:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Wall Street Zen moved Caribou from Hold to Sell on September 19, 2026. The USD 7.75 consensus target covers Caribou Biosciences stock.

CRBU, US1420381089, Illustration mit AI erstellt.

Caribou Biosciences (US1420381089) stock received a Hold-to-Sell downgrade from Wall Street Zen on September 19, 2026, according to MarketBeat. The move contrasts with a broader Moderate Buy consensus and keeps analyst expectations sharply above the company stock's market value.

Rating split meets weak revenue

Caribou reported revenue of USD 1.50 million in the second quarter of 2026, below the USD 2.28 million consensus estimate, according to MarketBeat. The company reported a loss of USD 0.24 per share for the same period against a USD 0.32 expected loss, making the earnings comparison more favorable than the revenue result.

The September 19, 2026 MarketBeat report also cited a consensus price target of USD 7.75 from five analysts, including three Buy ratings, one Strong Buy rating and one Sell rating. Bank of America had cut its target from USD 6.00 to USD 5.00 on August 14, 2026, while retaining a Buy rating, according to MarketBeat.

Pipeline remains the central value driver

Caribou is a clinical-stage biotechnology company developing genome-edited, allogeneic cell therapies for blood cancers and solid tumors. Its pipeline includes CB-010, CB-011, CB-012 and CB-020, while its Cas12a chRDNA platform is designed to support targeted genetic modifications in immune cells, according to the company's investor-relations page at Caribou Biosciences.

Investing.com lists November 10, 2026 as Caribou's next earnings date. That report will give investors a fresh comparison for revenue, cash use and progress across the clinical pipeline.

Market value stands at USD 119.5 million

Caribou Biosciences had a market capitalization of USD 119.5 million as of October 5, 2026. The stock was trading at USD 1.21 on Nasdaq at 12:12 p.m. ET on October 5, 2026, against a 52-week range of USD 1.17 to USD 3.54.